Elizabeth Barrett - 09 Aug 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Reporting relationship: Director
Issuer ticker: SAGE
Reported as of: 09 Aug 2023
Net transaction value: +$37,279
SEC form: 4
Accepted by SEC: 11 Aug 2023, 08:51:18 UTC
Prior SEC filing: 16 Jun 2023
Next SEC filing: 11 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Elizabeth Barrett

Key filing fact

Elizabeth Barrett filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 11 Aug 2023.

Key facts

This page summarizes Elizabeth Barrett's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Aug 2023, 08:51.

Change

Previous filing in this sequence was filed on 16 Jun 2023.
Current net transaction value: +$37,279.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SAGE transaction

Common Stock

Purchase

Transaction value: $37,279
Shares: +2,000
Change %: +200%
Price: $18.64
Shares after: 3,000
Date: 09 Aug 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades at prices ranging from $18.63 USD to $18.6398 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.